Literature DB >> 3332176

Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation.

J Peralvo1, A Bacigalupo, P A Pittaluga, D Occhini, M T Van Lint, F Frassoni, E Nardelli, A Transino, M Pantarotto, A M Marmout.   

Abstract

This is a retrospective analysis of marrow function in 171 recipients of an HLA-matched bone marrow transplant (BMT). Only patients with detectable hemopoiesis as indicated by leukocyte counts greater than 1.0 x 10(9)/l and platelet counts greater than 25 x 10(9)/l who were alive on day 30 were entered in the study. Poor marrow function was detected in 24 (14%) patients as indicated by a decrease in the peripheral blood counts to less than 40% of the maximal preceding values post-transplant in association with reduced marrow cellularity. Leukopenia (n = 4), thrombocytopenia (n = 3) or a combination of the two (n = 17) occurred 62 +/- 23 (SEM) days post-transplant and was associated with acute graft-versus-host disease (AGVHD) grade II or more and infection (n = 19) in the absence of clear rejection or persistence/recurrence of malignant disease. A multivariate analysis showed that AGVHD was the major risk factor (p = 0.001) for developing poor graft function. In the 24 patients with poor graft function, hemopoietic recovery was strongly associated with resolution of AGVHD and of infections. Their survival (27%) was the same as survival for other patients matched for GVHD who had no pancytopenia. The causes of death were GVHD (n = 13), pneumonia (n = 3) and infections (n = 1). This study draws attention to a particular type of poor graft function following allogeneic BMT that is characterized by (1) normal timing and quality of engraftment, (2) AGVHD of grade II or greater, (3) progressive and severe pancytopenia, and (4) multiple infections with poor clinical condition.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3332176

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.

Authors:  Hirohisa Nakamae; Barry Storer; Brenda M Sandmaier; David G Maloney; Chris Davis; Lawrence Corey; Rainer Storb; Michael Boeckh
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

2.  Severe autoimmune thrombocytopenia after allogeneic bone marrow transplantation for aplastic anemia.

Authors:  A Tomonari; A Tojo; T Lseki; J Ooi; H Nagayama; K Ogami; T Maekawa; N Shirafuji; K Tani; S Asano
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

3.  A case of chronic graft-versus-host-disease following allogeneic peripheral blood stem cell rescue for poor graft function after bone marrow transplantation.

Authors:  H J Kim; I J Chung; J J Lee; J S Seo; M R Park; K S Choi; H Kook; T J Hwang
Journal:  Korean J Intern Med       Date:  1998-02       Impact factor: 2.884

4.  Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single-center retrospective study.

Authors:  Wei-Ran Lv; Ya Zhou; Jun Xu; Zhi-Ping Fan; Fen Huang; Na Xu; Li Xuan; Peng-Cheng Shi; Hui Liu; Zhi-Xiang Wang; Jing Sun; Qi-Fa Liu
Journal:  Cancer Med       Date:  2021-10-20       Impact factor: 4.452

Review 5.  Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Stavroula Masouridi-Levrat; Federico Simonetta; Yves Chalandon
Journal:  Front Immunol       Date:  2016-09-16       Impact factor: 7.561

Review 6.  Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation.

Authors:  Juan Chen; Hongtao Wang; Jiaxi Zhou; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-08-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.